Department of Parasitology and Mycology, School of Medicine Hamadan University of Medical Sciences, Hamadan, Iran.
Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.
Microb Pathog. 2021 Mar;152:104615. doi: 10.1016/j.micpath.2020.104615. Epub 2020 Nov 24.
Blastocystis is one of the most common pathogens of the human intestine, caused by an emerging parasite, which can lead to severe symptoms and even death in immunocompromised patients. We aimed to determine the global prevalence of Blastocystosis infection in people with immunodeficiency. A systematic literature search was conducted on Web of Science, Scopus, Google scholar, Science Direct and MEDLINE databases to select all observational studies reporting the prevalence of Blastocystosis infection in Worldwide, based on different diagnostic methods in immunocompromised patients of any age and published from inception to February 2019. Pooled estimates and 95% confidence intervals (95% CIs) were calculated using random effects models and in addition, the I statistic was calculated. The geographic distribution of studies was evaluated and the diagnosis of Blastocystis was compared by various techniques. Electronic databases were reviewed for Blastocystosis infection in HIV/AIDS, cancer and other immunocompromised patients, and meta-analyses were conducted to calculate the overall estimated prevalence. Total68 eligible studies were included. The estimated pooled prevalence rate of Blastocystosis infection in immunocompromised patients was overall 10% (95% CI, 7-13%; I 96.04%) (P < 0.001), of whom 21% [18-25] were in Australia, 12% [4-24] in America, 11% [6-17] in Europe and 10% [5-15], 7% [3-13] in Asia and Africa, respectively. It was calculated that the estimated pooled prevalence rate of Blastocystosis infection in immunocompromised patients was overall 10% and the prevalence estimates ranged from 0.44 to 72.39. Also, overall the prevalence of parasites co-infection in immunocompromised patients was detected as 0.024%. Our finding showed that immunocompromised people show a high prevalence of Blastocystosis infection compared to the control population. Adequate information on the prevalence rate is still missing from many countries. However, current information underscore that Blastocystis should not be neglected.
芽囊原虫是人体肠道中最常见的病原体之一,由一种新兴寄生虫引起,在免疫功能低下的患者中可导致严重症状,甚至死亡。我们旨在确定免疫缺陷人群中芽囊原虫感染的全球流行率。我们在 Web of Science、Scopus、Google Scholar、Science Direct 和 MEDLINE 数据库中进行了系统的文献检索,以选择所有基于不同诊断方法在任何年龄免疫功能低下患者中报告芽囊原虫感染流行率的观察性研究,这些研究在 2019 年 2 月之前发表。使用随机效应模型计算汇总估计值和 95%置信区间 (95%CI),并计算 I 统计量。评估研究的地理分布,并比较不同技术的芽囊原虫诊断。审查电子数据库以了解 HIV/AIDS、癌症和其他免疫功能低下患者中的芽囊原虫感染情况,并进行荟萃分析以计算总体估计流行率。共纳入 68 项符合条件的研究。免疫功能低下患者中芽囊原虫感染的估计总流行率为 10%(95%CI,7-13%;I 96.04%)(P<0.001),其中 21%[18-25]来自澳大利亚,12%[4-24]来自美国,11%[6-17]来自欧洲,10%[5-15],7%[3-13]来自亚洲和非洲。计算出免疫功能低下患者中芽囊原虫感染的估计总流行率为 10%,流行率估计值范围为 0.44-72.39。此外,总体而言,免疫功能低下患者寄生虫合并感染的患病率为 0.024%。我们的研究结果表明,与对照人群相比,免疫功能低下者的芽囊原虫感染率较高。许多国家仍然缺乏有关流行率的充分信息。然而,目前的信息强调芽囊原虫不容忽视。